Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery (IVAPAP)
A Double Blind, Randomized, Placebo-controlled Study to Investigate the Effectiveness of IV Acetominophen Administered During Functional Endoscopic Sinus Surgery in Reducing the Use of Opiates to Treat Postoperative Pain
調査の概要
詳細な説明
Unrelieved postoperative pain may result not only in suffering and discomfort, but may also lead to multiple physiological and psychological consequences which can contribute to adverse perioperative outcomes. Inadequate perioperative analgesia can potentially contribute to a higher incidence of myocardial ischemia. Additionally, the use of opioids has been associated with major side effects that can include impaired wound healing and delayed gastrointestinal (GI) motility that results in prolonged postoperative ileus.
Intravenous acetyl-para-aminophenol (APAP, also known as acetaminophen) is considered as the non-opioid analgesic of choice to treat postoperative mild and moderate pain, and has been demonstrated in several randomized trials to be both safe and effective at reducing acute post-operative pain in both children and adults. Furthermore, in the treatment of severe pain, it can reduce the need for opioid-analgesics while exhibiting a relatively limited side effect profile when compared to opioids and nonsteroidal anti-inflammatory drugs.
Chronic rhinosinusitis (CRS) describes a group of disorders characterized by inflammation of the nasal mucosa and/or paranasal sinuses for at least 12 consecutive weeks. In the United States, CRS affects approximately 30 million people, and represents 2% of the primary diagnoses in physician office visits, resulting in an estimated 200,000 sinus procedures annually. Patients suffering from CRS that is refractory to medical management complain of symptoms that include fatigue, headache, nasal drainage, facial pain and pressure, and decreased sense of smell. Functional endoscopic sinus surgery (FESS) represents a surgical approach to treating CRS that is unresponsive to medical management. Outcomes studies have identified FESS as efficacious at reducing the majority of symptoms related to CRS. Despite this, pain associated with CRS remains a significant co-morbidity that often is resistant to both medical and surgical management. Reducing the incidence and severity of acute post-operative pain is paramount to reducing the development of chronic pain that may exacerbate a patient's existing pain. The use of pre- and intra- operative IV acetaminophen thus serves as a unique pain management modality in this setting, as it has the potential for reducing post-operative complications and pain, with the additional benefit of minimal intraoperative bleeding, an undesirable complication often associated with FESS and with the use of non-steroidal anti-inflammatory drugs (NSAIDs).
The use of IV acetaminophen in ear, nose, and throat (ENT) surgery is not a novel endeavor. Indeed, studies have demonstrated the efficacy and safety of IV acetaminophen for use in tonsillectomy and FESS. We wish to provide a more comprehensive analysis of pain management in the setting of FESS in the following ways :
- by administering IV acetaminophen perioperatively (before start of surgery, and after surgery completion;
- by employing a pain score of 4 (whereas other studies use 3) as a cutoff for breakthrough pain; and,
- by addressing novel outcomes including patient sedation and patient satisfaction, in addition to opioid analgesic use.
In our institution, we have completed a preliminary pilot study exploring the use of intravenous anesthesia which included acetaminophen during bilateral endoscopic sinus surgery. Secondary outcomes measured during the study included:
- Pain
- Rescue analgesic use
- Nausea/Vomiting
- Time spent in recovery
- Successful discharge from the PACU and the Hospital
Our pilot data has reaffirmed that the procedure is overall benign, with few associated risks and adverse events. Of note, none of the patients in our preliminary study required admission to the hospital after surgery for further observation as a result of uncontrolled pain or nausea. Based on this experience, we would like to explore the efficacy of intravenous acetaminophen (Ofirmev), a non opioid/non steroidal analgesic, in endoscopic sinus surgery.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- The University of Texas Health Sciences Center at Houston
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
- Patients undergoing surgical management for CRS (with or without polyps)
- Operating time must be at least 2 hours in duration.
- Number of sinuses involved must be 3 or greater
Exclusion criteria:
- History of hypersensitivity to acetaminophen
- End stage renal disease
- End stage liver disease
- History of chronic pain, or use of opioid medication in the previous two weeks
- Severe depression or anxiety
- Use of gabapentin or any other pain modulator
- History of acute sinusitis or mucocele
- History of seizures
- Known or suspected history of alcohol or drug abuse
- Known or suspected history of morphine intolerance
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:IV Acetaminophen
The experimental group will receive a preoperative dose of 1000mg IV acetaminophen over 15 minutes.
This will occur at least 15 minutes before the start of surgery.
Another 1000mg dose of IV acetaminophen will be administered 4 hours after the first dose.
A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
|
1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
他の名前:
|
|
プラセボコンパレーター:Control
The control group (Placebo) will receive 100 mL of 0.9% normal saline in place of IV acetaminophen in the same manner as the experimental group; the investigator/physician in question will be blinded to the agent that is being administered.
Patients will be discharged with instruction to continue APAP 500 mg PO every 6-8 hours.
A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
|
100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pain Level Assessed Using a Visual Analogue Scale (VAS) Scale
時間枠:15 minutes and 120 minutes Post-Operatively
|
VAS is a validated, self-reported data sheet assessing average pain intensity.
Possible scores range from 0 (no pain) to 10 (highest level of pain).
|
15 minutes and 120 minutes Post-Operatively
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Total Doses of Postoperative Opiate (Morphine) Use
時間枠:During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
The total amount of morphine utilized in Postoperative Acute Care Unit (PACU) will be recorded.
One dose is a 1mg bolus of morphine.
|
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
|
Number of Participants Who Received Intraoperative Supplemental Fentanyl
時間枠:During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
Number of participants who received intraoperative supplemental fentanyl.
The decision to administer fentanyl is based on hemodynamic changes, such as increasing blood pressure and heart rate.
|
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
|
Number of Participants Who Experienced Postoperative Morbidity (Nausea)
時間枠:During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
Post-operative nausea will be monitored and measured through direct observation and nursing clinical record
|
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
|
Postoperative Vital Sign (Systolic Blood Pressure)
時間枠:During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.
|
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
|
Postoperative Vital Sign (Diastolic Blood Pressure)
時間枠:During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.
|
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
|
Postoperative Vital Sign (Pulse)
時間枠:During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.
|
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
|
Postoperative Vital Sign (Temperature)
時間枠:During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.
|
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
|
Postoperative Vital Sign (Respiratory Rate)
時間枠:During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.
|
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
|
協力者と研究者
協力者
捜査官
- 主任研究者:Davide Cattano, MD, PhD、The University of Texas Health Sciences Center at Houston
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- HSC-MS-12-0111
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。